nifuroxazide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
5-nitrofuran derivatives 1928 965-52-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nifuroxazide
  • dicoferin
  • nifuroxazid
  • pentofuryl
  • Molecular weight: 275.22
  • Formula: C12H9N3O5
  • CLOGP: 1.90
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 120.65
  • ALOGS: -3.42
  • ROTB: 4

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.514 Moderate 0.66
caco2-efflux Caco-2 efflux ratio (BA/AB) 2.393 Moderate 0.66
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 29.512 10^-6 cm/s Moderate 0.66
dh-clint Dog hepatocyte intrinsic clearance 33.189 uL/min/10^6 cells Moderate 0.66
dppb Dog plasma protein binding (% unbound) 18.850 % Moderate 0.66
fcs-ppb Fetal calf serum protein binding (% unbound) 28.100 % Moderate 0.66
herg hERG pIC50 4.258 pIC50 Moderate 0.66
hh-clint Human hepatocyte intrinsic clearance 62.230 uL/min/10^6 cells Moderate 0.66
hlm-clint Human liver microsomal intrinsic clearance 10.423 uL/min/mg protein Moderate 0.66
hppb Human plasma protein binding (% unbound) 10.780 % Moderate 0.66
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ZAP70 66
kinase-selectivity-class ACVR2A,ACVR2B,AURKA,AURKB,AXL,BRAF,CAMK2D,CDK4,CDK9,DDR1,DYRK1B,EPHB4,GRK2,GSK3A,GSK3B,IRAK1,MAP2K3,MAP2K6,MAP3K14,MAP3K21,MAPK1,MAPK12,MAPK7,MARK4,MET,PDPK1,PRKDC,SIK2,STK33,SYK,TEK,TTK,ULK1 33
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 6.792 Moderate 0.66
mh-clint Mouse hepatocyte intrinsic clearance 202.768 Moderate 0.66
mppb Mouse plasma protein binding (% unbound) 20.940 Moderate 0.66
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 3.206 Moderate 0.66
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 22.990 % Moderate 0.66
rh-clint Rat hepatocyte intrinsic clearance 149.279 uL/min/10^6 cells Moderate 0.66
rh-fuinc Rat hepatocyte fraction unbound in incubation 88.260 % Moderate 0.66
rppb Rat plasma protein binding (% unbound) 11.180 % Moderate 0.66
solubility-dd Solubility at pH 7.4 in DMSO 578.096 uM Moderate 0.66

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Trimethylaminuria 178.16 91.20 20 460 172 90627795
Pseudomembranous colitis 125.07 91.20 21 459 3847 90624120
Megacolon 121.81 91.20 19 461 2195 90625772
Intestinal perforation 92.61 91.20 20 460 13861 90614106

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Trimethylaminuria 178.19 62.32 21 810 194 110588274
Pseudomembranous colitis 113.14 62.32 22 809 6369 110582099
Megacolon 108.81 62.32 20 811 4285 110584183
Dysbiosis 87.78 62.32 15 816 2117 110586351
Intestinal perforation 82.19 62.32 21 810 20923 110567545
Peritonitis 77.48 62.32 22 809 32585 110555883
Clostridium difficile infection 75.50 62.32 24 807 52105 110536363
Inhibitory drug interaction 63.28 62.32 13 818 4934 110583534

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A07AX03 ALIMENTARY TRACT AND METABOLISM
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
INTESTINAL ANTIINFECTIVES
Other intestinal antiinfectives
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:67079 anti-inflammatory agent

Related Drugs by ATC class:

A07AX Other intestinal antiinfectives 3 drugs
acetarsolbroxyquinolinenifurzide

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.75 acidic
pKa2 10.28 acidic
pKa3 2.04 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Signal transducer and activator of transcription 3 Transcription factor EC50 5.52 CHEMBL

External reference:

IDSource
D07111 KEGG_DRUG
C0068742 UMLSCUI
CHEBI:135136 CHEBI
CHEMBL244888 ChEMBL_ID
DB13855 DRUGBANK_ID
C013150 MESH_SUPPLEMENTAL_RECORD_UI
5337997 PUBCHEM_CID
12358 IUPHAR_LIGAND_ID
1578 INN_ID
PM5LI0P38J UNII
31782 RXNORM
005828 NDDF
703471002 SNOMEDCT_US
703472009 SNOMEDCT_US
PM5LI0P38J INXIGHT DRUGS

Pharmaceutical products:

None